Data are available directly on the paper, and have been collected by a critical reading of the scientific literature of interest. The source of the publications is the PubMed database.

Introduction {#sec001}
============

The present study aims at finding out whether there is a clear connection between the toxicity of novel anticancer drugs and their cost. To this end, we explore the information related to the rate of Severe Adverse Events (SAE) and the discontinuation (D) of a qualified set of oncological drugs. Such rates contribute to the creation of a so-called Toxicity Index (TI). Specifically, we have created a high-quality dataset by investigating the phase III studies in the context of the approval by the US Food and Drug Administration (FDA) of the target agents and of their introduction in the clinical practice.

The motivations for our study are of economic and social nature. In fact, cancer is one of the most costly health conditions to manage worldwide \[[@pone.0183639.ref001]\]. Anticancer agents have represented the 43% of new drugs approved by the FDA in the last decade \[[@pone.0183639.ref002]\]. The increase of drug spending in oncology is mainly due to the recent introduction of new targeted and immunotherapy agents \[[@pone.0183639.ref003]\], which have improved the outcome of cancer patients in terms of Overall Survival (OS) and Progression-Free Survival (PFS) compared to conventional chemotherapy. Although these agents are generally associated with a lower rate of treatment D due to drug toxicity, their impact on patients\' Quality of Life (QoL) should not be overlooked. Improving patients' QoL and their compliance to treatments will represent the challenge for cancer researchers in the future years. Indeed, by a purely economic perspective, reducing the toxic effects of these treatments will allow to decrease the abstention from work days and to increase productivity, hence leading to a wider access to cures due to a better economic status \[[@pone.0183639.ref004]--[@pone.0183639.ref008]\].

This paper can be properly inserted in the frame of pharmacoeconomics, which is a scientific discipline related to the cost and the value of drugs and provides suggestion for the optimal allocation of the healh care resources. This conceptualization was proposed by Townsend in 1987 \[[@pone.0183639.ref009]\], who identified the Pharmacoeconomics as "the description and the analysis of costs of therapeutic approch substained by the Health System and Society". However, the first definition of Pharmacoeconomics dates back to 1977 when Weinstein and Stason \[[@pone.0183639.ref010]\] published a paper dealing with economic analysis in health field.

On the current scenario of rapidly rising health care costs, pharmaeconomic techniques are becoming increasingly relevant to analyze the cost-effectiveness and economic sustainability of emerging drugs \[[@pone.0183639.ref011]\]. Among such techniques, cluster analysis plays a relevant role. In fact, cluster analysis is used to identify groups of similar data based on selected variables and is particularly suitable for their comparison. The versatility of such a statistical technique explains also its popularity in many fields of applied science \[[@pone.0183639.ref012]--[@pone.0183639.ref020]\]. Indeed, cluster analysis seems to be appropiate for performing a global study of the connection between drug effectiveness, toxicity and cost. In this context, it is worth mentioning Perrier et al \[[@pone.0183639.ref014]\], who explored the transferability of health cost assessment between Italy and France. The authors constructed a hierarchical structure using cluster analysis and identified four different clusters based on diagnosis, surgery, chemotherapy and follow-up. Their findings showed that a high variability was present between this two countries, suggesting a low transferability of cost evaluations across Italy and France. Two years later, Liao et al. \[[@pone.0183639.ref015]\] performed an observational study on 18,380 patients with end-stage renal disease who initiated hemodialysis. By using K-means and hierarchical cluster analyses with either flexible beta or Ward's methods, they identified 4 clusters based on sample sizes and change of cost patterns, finding that higher costs were correlated with more increasing comorbidity scores.

In our study we are different from the quoted papers since we first create a dataset containing clinical and economic information about all the oncological target agents approved in clinical practice. In this respect, it is important to recall that a target agent is a drug that is able to recognize one or more specific molecules expressed by tumor cells, immune cells or, more generally, by tumor microenvironment in cancer patients. The identification procedure has been rather complex -it mirrors the complexity of the faced problem- and represents a relevant step of the research.

Furthermore, we have employed a method based on Voronoi tessellation \[[@pone.0183639.ref021]\], which represents a potential visualization of the subgroups identified by the cluster analysis. Voronoi diagram is a kind of decomposition of a given metric space based on the distance (which is Euclidean in the original formulation of Voronoi) to specified sites called centroids \[[@pone.0183639.ref021]\]. Particularly, each centroid recognizes data that are nearer to it than to the other centroids in accord to the given distance. By applying this technique, we are able to explore the way in which clusters of toxicity and costs overlap, hence giving information on the relationship between drug toxicity and related cost.

As we will see below, to gain more insights we depart from the original formulation of Voronoi and consider also minimum and maximum distances.

Cluster analysis, with a specific Voronoi diagrams approach, has been recently applied in the economic field \[[@pone.0183639.ref022]--[@pone.0183639.ref025]\]. In 2009, Liu et al. \[[@pone.0183639.ref022]\] explored the distribution of rural assessment using this technique. They showed that the distance from highways and rivers were the two factors that majorly influenced the distribution of rural settlements. More recently, Vaz et al. \[[@pone.0183639.ref023]\] reported a significant difference in term of regional innovation patterns as a consequence of istitutional innovation profiles.

As already mentioned above, we here investigate, through a cluster analysis procedure, whether there is a correlation between the cost of molecularly targeted and immnotherapy agents and their toxicity in terms of SAE and D rates.

To the best of our knowledge, this is the first paper dealing with toxicity and cost of target agents in oncology through a cluster analysis. More than this, the construction of the dataset on the basis of an exhaustive literature review is also a novelty in the oncological studies.

The rest of the paper is organized as follows. Section 2 collects the results of the analysis, while Section 3 provides a discussion of them. In Section 4 we present how the used dataset has been constructed and illustrate its main statistical properties. Furthermore, Section 4 contains also the description of the employed methodological tools, with a detailed explanation of the cluster analysis.

Materials and methods {#sec002}
=====================

Costruction of the dataset {#sec003}
--------------------------

The construction of the dataset has been implemented through a critical analysis of a wide set of clinical studies.

The selection of the relevant researchs has been carried out according to the instructions contained in the PRISMA \[[@pone.0183639.ref026]\] ([S1 File](#pone.0183639.s001){ref-type="supplementary-material"}). The scientific literature of interest has been identified from keywords selections on the PubMed database, in a period ranging from 1965 to 2016. Specifically, the research has been conducted by combining the words \"cancer\", \"neoplasm\", \"solid tumor\" and \"clinical trial\" with the name of each target agent.

As a second step, we have identified the papers dealing with human studies and randomized trials published in English and meeting the following criteria: 1) phase III studies conducted in patients with cancer; 2) random assignment of participants to treatment with a target therapy or a control (standard of care, placebo or best supportive care). In case of several publications related to the same experiment, only the most recent one or the most complete referring to included trial has been considered. Phase I and phase II trials has been excluded because of their variability and the lack of sufficient controls.

For each of the obtained papers we have reported the scientific study, the name of all authors, the name of the journal, the reference year, the number of the volume and the reference pages.

The resulting list of studies on target agents has been explored to assess the variables of interest related to the specific agent, i.e.: number of patients treated with target agents in the clinical studies, PFS (defined as the time from the start of therapy to disease progression or death), rate of all-grade AE and SAE (which leads to the necessity of medical assistence, hospitalization or drug interruption) and the D rate due to drug toxicity.

For the present research, we consider as variables the rate of SAE and the D rate, leaving the other ones for future studies.

Information on the costs of the target agents has been derived directly from their websites. All costs are expressed in American US Dollars.

Cluster analysis {#sec004}
----------------

Cluster analysis and Voronoi tesselation were performed by R software version 3.3.0 for Windows (62 megabytes, 32/64 bit). We have compared the clusters of target agents obtained when taking toxicity and when taking costs.

For what concerns toxicity, we have considered SAE and D rates as relevant variables. They are the parameters concurring in our conceptualization of the *Toxicity Index* (*TI*, hereafter).

The procedure of centroids selection has been implemented accordingly to clinical and scientific criteria, in order to represent the most meaningful groups of combinations of the two variables. For this analysis, we have reasonably considered five centroids as follows: *ϕ*~1~ = (10,5); *ϕ*~2~ = (30,15); *ϕ*~3~ = (45,10); *ϕ*~4~ = (60,20); *ϕ*~5~ = (75,25), where the first component is the SAE value while the second one represents the D rate. In particular, centroid *ϕ*~1~ is associated with low rate of SAE and low D rate, which leads to a low TI; *ϕ*~2~ has low-medium rate of SAE and medium D rate, which means low-medium TI; *ϕ*~3~ has medium rate of SAE and low-medium D rate (medium TI); *ϕ*~4~ represents medium-high rate of SAE and medium-high D rate (medium-high TI); *ϕ*~5~ identifies a cluster with high rate of SAE and high D rate (high TI). The cluster obtained by centroid *ϕ*~*h*~ will be denoted by *C*~*h*~, for each *h* = 1,2,3,4,5. Moreover, by denoting the observations of SAE and D rates by the variables *x* and *y*, respectively, we also denote components of the centroid *ϕ*~*h*~ = (*ϕ*~*h*,*x*~,*ϕ*~*h*,*y*~), for each *h* = 1,2,3,4,5.

Clusters are identified by the nearness of the target agent toxicity with the centroids. At this aim, we apply three different concepts of distance: an Euclidean one--in accord to the original model of Voronoi-, the maximum and the minimum. Formally, for any given target agent *j* = 1,2,...,37 with SAE rate *x*~*j*~ and D rate *y*~*j*~, we define $$d_{E}\left( {j,\phi_{h}} \right) = \sqrt{\left( {x_{j} - \phi_{h,x}} \right)^{2} + \left( {y_{j} - \phi_{h,y}} \right)^{2}}$$ $$d_{M}\left( {j,\phi_{h}} \right) = max\left\{ {{|x}_{j} - \phi_{h,x}|,|y_{j} - \phi_{h,y}|} \right\}$$ $$d_{m}\left( {j,\phi_{h}} \right) = min\left\{ {{|x}_{j} - \phi_{h,x}|,|y_{j} - \phi_{h,y}|} \right\}$$

According to the specific metric selected, we derive the clusters of target agents as follows: $$C_{h}^{K} = \left\{ {j = 1,\ldots,37|\ d_{K}\left( {j,\phi_{h}} \right) < d_{K}\left( {j,\phi_{\overline{h}}} \right),\forall\overline{h} \neq h} \right\},\ \forall\ K = E,M,m,\qquad\forall\ h = 1,2,3,4,5.$$

For what concerns the costs of the target agents, we have implemented two simple clusterings based on two variables. First, we have grouped the investigated drugs into three groups on the basis of 1-month cost patterns: cost less than 7,000\$ (Group A), cost ranging from 7,000 to 11,000\$ (Group B) and cost greater than 11,000\$ (Group C). In the same way, drugs were grouped according to their costs extimated for the complete treatment for each patient within 3 groups: cost less than 40,000\$ (Group D), cost ranging from 40,000\$ to 80,000\$ (Group E) and cost greater than 80,000\$ (Group F).

Results {#sec005}
=======

At the end of text analysis, we have obtained 4,803 studies concerning the use of molecular targeted drugs in cancer patients (the list of drugs is reported in the first column of [Table 1](#pone.0183639.t001){ref-type="table"}).

10.1371/journal.pone.0183639.t001

###### List of target agents employed in oncological patients.

Their characteristics are related to drug efficacy in terms of median Progression-Free Survival (PFS) and drug toxicity in terms of rate of all-grade, severe adverse events and discontinuation rate. BCC = Basal-cell Carcinoma; GIST = Gastrointestinal Stromal Tumor; NSCLC = Non Small Cell Lung Cancer; RCC = Renal Cell Carcinoma.

![](pone.0183639.t001){#pone.0183639.t001g}

  Target Agent                                    First Authors, Year    Reference   Cancer Type          Number of Patients   Median PFS (Months)   All grade Adverse Events (%)   Severe Adverse Events(%)   D Rate (%)
  ----------------------------------------------- ---------------------- ----------- -------------------- -------------------- --------------------- ------------------------------ -------------------------- ------------
  Abiraterone acetate (first line therapy)        Charles JR, 2013       27          Prostate             546                  16.5                  99                             48                         10
  Abiraterone acetate (successive line-therapy)   de Bono S, 2011        28          Prostate             797                  5.6                   23                             7                          19
  Afatinib                                        Sequist LV, 2013       29          NSCLC                230                  11.1                  NA                             49                         8
  Bevacizumab                                     Friedman HS, 2009      30          Glioblastoma         82                   5.6                   100                            65.8                       17.7
  Bevacizumab                                     Escudier B, 2007       31          RCC                  327                  10.2                  97                             29                         28
  Bevacizumab (first line therapy)                Hurwitz H, 2004        32          Colorectal           411                  10.6                  NA                             84,9                       8.4
  Bevacizumab (successive line-therapy)           Bennouna J, 2013       33          Colorectal           409                  5.7                   98                             64                         16
  Cabozantinib                                    Eisei R, 2013          34          Thyroid              219                  11.2                  NA                             69                         16
  Cetuximab                                       Vermorken JB, 2008     35          Head and Neck        222                  5.5                   NA                             82                         20
  Cobimetinib + Vemurafenib                       Larkin J, 2014         36          Melanoma             247                  9.9                   95                             62                         12
  Crizotinib                                      Shaw AT, 2013          37          NSCLC                173                  7.7                   NA                             33                         6
  Enzalutamide (first line therapy)               Beer TM, 2015          38          Prostate             800                  8.3                   34                             28                         8
  Enzalutamide (successive line-therapy)          Scher HI, 2012         39          Prostate             872                  5.7                   97                             43                         6
  Erlotinib                                       Moore MJ, 2007         40          Pancreas             282                  3.8                   100                            61                         10
  Erlotinib (first line therapy)                  Rosell R, 2012         41          NSCLC                86                   9.7                   98                             45                         13
  Erlotinib (maintainance therapy)                Cappuzzo F, 2010       42          NSCLC                438                  2.9                   NA                             11                         16
  Everolimus                                      Baselga J, 2012        43          Breast               482                  7.8                   NA                             23                         19
  Lenvatinib                                      Schlumberger M, 2015   44          Thyroid              261                  14.7                  97.3                           75.9                       14.2
  Nivolumab                                       Brahmer J, 2015        45          Squamous NSCLC       135                  3.5                   58                             7                          3
  Nivolumab                                       Borghaei H, 2015       46          Non-Squamous NSCLC   292                  2.3                   69                             10                         5
  Nivolumab                                       Robert C, 2015         47          Melanoma             210                  5.1                   74.3                           11.7                       2.4
  Nivolumab                                       Motzer RJ, 2015        48          RCC                  410                  4.6                   79                             19                         8
  Palbociclib (+letrozole)                        Finn RS, 2015          49          Breast               84                   20.2                  99                             76                         33
  Palbociclib (+fulvestrant)                      Turner NC, 2015        50          Breast               347                  9.2                   97.7                           69,3                       2.6
  Pembrolizumab                                   Robert C, 2015         51          Melanoma             277                  4.1                   72.9                           75                         6.9
  Ramucirumab                                     Fuchs CS, 2014         52          Gastric              238                  2.1                   94                             57                         11
  Ramucirumab                                     Garon EB, 2014         53          NSCLC                628                  4.5                   98                             79                         15
  Ramucirumab                                     Tabernero J, 2015      54          Colorectal           536                  5.7                   83                             36                         11
  Regorafenib                                     Grothey A, 2013        55          Colorectal           505                  1.9                   93                             54                         44.8
  Sonidegib                                       Midgen MR, 2015        56          BCC                  79                   13.1                  95                             31                         22
  Sorafenib                                       Escudier B, 2007       57          RCC                  451                  5.5                   NA                             34                         10
  Sunitinib                                       Motzer RJ, 2009        58          RCC                  375                  11                    NA                             7                          38
  Sunitinib                                       Demetri GD, 2006       59          GIST                 207                  6.4                   83                             20                         9
  T-DM1                                           Verma S, 2012          60          Breast               495                  9.6                   95.9                           15,5                       5
  Temsirolimus                                    Hudes G, 2007          61          RCC                  209                  3.8                   NA                             11                         7
  Trametinib + Dabrafenib                         Long GV, 2014          62          Melanoma             211                  9.3                   95                             32                         9
  Ziv-Aflibercept                                 Van Cutsem E, 2012     63          Colorectal           612                  6.9                   99.2                           83,5                       26.8

Therefore, 2,914 of the 4,083 original papers have been excluded because of phase I studies, observational, in vitro, reviews or letters about targeted therapies. Of the 1,889 remained studies, 1,852 were excluded because dealing with phase II or because not containing data on the SAE and D rates.

As a result, we have found 23 target agents that are used in 37 different therapeutic settings \[[@pone.0183639.ref027]--[@pone.0183639.ref063]\] ([Table 1](#pone.0183639.t001){ref-type="table"}).

The identification of the relevant papers is described in [Fig 1](#pone.0183639.g001){ref-type="fig"}, where it is presented a block diagram of the PRISMA procedure.

![Study selection according to PRISMA statement.](pone.0183639.g001){#pone.0183639.g001}

[Table 2](#pone.0183639.t002){ref-type="table"} contains the main statistical indicators of the dataset. The mean/std. dev. ratio allows additional considerations about the heterogeneity within the clusters, which is low, supporting that each cluster includes similar drugs both in terms of SAE and D rates.

10.1371/journal.pone.0183639.t002

###### Main statistical indicators of the dataset.

![](pone.0183639.t002){#pone.0183639.t002g}

                   Number of patients   DRUG EFFECTIVENESS   DRUG TOXICITY           
  ---------------- -------------------- -------------------- --------------- ------- ------
  Mean             356                  7.60                 86              44      14
  Std. Dev.        205                  4.14                 20              26      10
  Mean/Std. Dev.   1.73                 1.84                 4.30            1.68    1.42
  Min              79                   1.9                  23              7       2.4
  Max              872                  20.2                 100             84.9    45
  Median           292                  6.4                  95              43      11
  Skewness         0.83                 1.03                 -2.06           0.10    1.48
  Kurtosis         0.23                 1.21                 3.95            -1.38   2.19
  Q1               211                  4.6                  81              20      8
  Q3               482                  9.9                  98              65.8    17.7

Concerning skewness, it is relevant to note that only the rate of all grade adverse events is negative (-2.06) with a curve of distribution characterized by a longer left tail with a median of patients developing at least an adverse event (95%) that overcross the mean of patients (86%). Further information can be added by observing the leptokurtic distribution of all grade adverse events (curtosis is 3.95), while the distribution of SAE is platykurtic (curtosis is -1.38).

It is also important to observe the response rates reported by target agents, which range from 1% to 80% ([Table 2](#pone.0183639.t002){ref-type="table"}). Such a result underlines the extreme variety of actions of these new generation agents that can improve patient survival without reducing tumour sizes.

[Fig 2*A*, 2*B* and 2*C*](#pone.0183639.g002){ref-type="fig"} show the clusters based on Euclidean distance, maximum distance and minimum distance, respectively. A spatial representation of the dynamic fields related to cluster analysis by Euclidean distance has been obtained by Voronoi diagram as reported in [Fig 3](#pone.0183639.g003){ref-type="fig"}.

![Cluster analysis based on Toxicity Index (TI) considering Euclidean distance (A), maximum distance (B) and minimum distance (C). The "+" represent the centroids.](pone.0183639.g002){#pone.0183639.g002}

![Voronoi tesselation based on Toxicity Index (TI) considering Euclidean distance.](pone.0183639.g003){#pone.0183639.g003}

The results of cluster analysis with Euclidean distance show a major similarity with the findings obtained by the maximum distance. In particular, such clustering criteria place in two different clusters only two drugs (Regorafenib, charaterized by SAE and D rates of 54 and 44.8, respectively, and Pembrolizumab, with SAE and D rates of 75 and 6.9, respectively. They belong to cluster 4 based on Euclidean distance and to cluster 5 according to the maximum distance). Differently, the clusters based on minimum distance are markedly different from both the other analyses.

It is interesting to note that the highest cost for a month and per PFS are represented by the combination of Cobimetinib and Vemurafenib and the lowest by Erlotinib (when used for patients with pancreatic cancer). The mean and median montly costs are 9,366 \$ and 8,627 \$, respectively. On the other hand, the mean and median costs per PFS are 73,154 \$ and 49,500 \$, respectively ([Table 3](#pone.0183639.t003){ref-type="table"}).

10.1371/journal.pone.0183639.t003

###### List of target agents approved for their use in cancer patients and related costs.

BCC = Basal-cell Carcinoma; GIST = Gastrointestinal Stromal Tumor; NSCLC = Non Small Cell Lung Cancer; RCC = Renal Cell Carcinoma.
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  Target Agent                                    Cancer Type          Monthly cost (\$)   Cost per PFS (\$)
  ----------------------------------------------- -------------------- ------------------- -------------------
  Abiraterone acetate (first line therapy)        Prostate             8,627               142,346
  Abiraterone acetate (successive line-therapy)   Prostate             8,627               48,311
  Afatinib                                        NSCLC                6,970               77,367
  Bevacizumab                                     Glioblastoma         4,400               24,640
  Bevacizumab                                     RCC                  4,400               44,880
  Bevacizumab (first line therapy)                Colorectal           2,680               28,408
  Bevacizumab (successive line-therapy)           Colorectal           2,680               15,276
  Cabozantinib                                    Thyroid              14,300              160,160
  Cetuximab                                       Head and Neck        7,000               38,500
  Cobimetinib + Vemurafenib                       Melanoma             26,300              260,370
  Crizotinib                                      NSCLC                11,500              88,550
  Enzalutamide (first line therapy)               Prostate             7,450               61,835
  Enzalutamide (successive line-therapy)          Prostate             7,450               42,465
  Erlotinib                                       Pancreas             2,450               9,310
  Erlotinib (first line thrapy)                   NSCLC                3,000               29,100
  Erlotinib (maintainance therapy)                NSCLC                3,000               8,700
  Everolimus                                      Breast               7,000               54,600
  Lenvatinib                                      Thyroid              13,945              204,992
  Nivolumab                                       Squamous NSCLC       12,600              44,100
  Nivolumab                                       Non-Squamous NSCLC   12,600              28,980
  Nivolumab                                       Melanoma             12,600              64,260
  Nivolumab                                       RCC                  6,984               32,126
  Palbociclib (+letrozole)                        Breast               9,850               198,970
  Palbociclib (+fulvestrant)                      Breast               9,850               90,620
  Pembrolizumab                                   Melanoma             23,017              94,370
  Ramucirumab                                     Gastric              13,000              27,300
  Ramucirumab                                     NSCLC                11,000              49,500
  Ramucirumab                                     Colorectal           13,000              74,100
  Regorafenib                                     Colorectal           7,600               14,440
  Sonidegib                                       BCC                  12,000              157,200
  Sorafenib                                       RCC                  6,600               36,300
  Sunitinib                                       RCC                  7,000               77,000
  Sunitinib                                       GIST                 7,000               44,800
  T-DM1                                           Breast               9,800               94,080
  Temsirolimus                                    RCC                  2,960               11,248
  Trametinib + Dabrafenib                         Melanoma             16,300              151,590
  Ziv-Aflibercept                                 Colorectal           11,000              75,900

Both [Fig 4*A* and 4*B*](#pone.0183639.g004){ref-type="fig"} show that heterogeneous cost distribution that doesn't clearly follow the cluster division based on TI. However, some illustrations of the relationship between toxicity and costs can be carried out at the single clusters level. For instance, as for the 1-month cost, the higher rate of drugs from Group C belongs to Cluster 5, whilst the higher percentage of drugs from Group A are included in Cluster 3. Concerning the total cost estimated for a single patient for the whole treatment, the higher rate of drugs belonging to Group D belongs to Cluster 4, whilst the higher percentage of drugs from Group F are in Cluster 5. The complete distribution of costs within the 5 clusters is reported in [Table 4](#pone.0183639.t004){ref-type="table"} and [Fig 5](#pone.0183639.g005){ref-type="fig"}.

![Cluster analysis based on Euclidean distance considering the drug costs for 1-month (A) or for the median total duration of therapy (B) for a single oncological patient. Green points represent drugs with low cost (Group A), violet points drugs with medium cost (Group B) and pink with high cost for 1-month of treatment (Group C).](pone.0183639.g004){#pone.0183639.g004}

![The distribution of different clusters into the three cost categories related to the amount for median Progression-Free Survival (PFS).](pone.0183639.g005){#pone.0183639.g005}

10.1371/journal.pone.0183639.t004

###### Distribution of costs within the 5 clusters based on TI.

![](pone.0183639.t004){#pone.0183639.t004g}

                1-month treatment cost   Total cost for a single patient (estimated by PFS)                  
  ------------- ------------------------ ---------------------------------------------------- ---- ---- ---- ----
  *Cluster 1*   33                       33                                                   34   44   44   12
  *Cluster 2*   22                       34                                                   44   11   56   33
  *Cluster 3*   50                       50                                                   0    25   50   25
  *Cluster 4*   38                       24                                                   38   63   0    37
  *Cluster 5*   14                       28                                                   58   29   29   42

Discussion {#sec006}
==========

Our paper concerns the study of the relationship between the toxicity and cost of newly approved target agents in the Oncology field. All the drugs approved by FDA have been considered. Variables related to SAE and D rates have been collected from published phase III studies.

Cluster analysis has been employed to explore such a relationship. Specifically, three different clustering criteria based on the Euclidean distance--in accord to the standard Voronoi tessellation definition- and maximum and minimum distances have been considered.

To interpret the outcomes of the analysis, we need to provide an intuitie description of the clustering criteria.

The minimum distance is the one that underestimate the toxicity level, in that it may place a drug in a low-toxicity cluster even if some related parameters are of remarkable high level.

Differently, the maximum distance is more "cautios" and overestimates the level of toxicity, since it may insert an agent into a high-toxicity cluster even when some toxicity parameters exhibit a low value.

The "fair" situation is captured by the Euclidean distance, which is the one used in the original Voronoi model. The comparison among the results of the clustering proedures suggests that taking a definition of toxicity that may imply its overestimation is closer to fairness than dealing with an understimation criterion.

It is important to note that the toxicity associated with oncological drugs implicates a high-cost management. In this regard, previous studies have tried to quantify this amount. For example, Roncato et al. \[[@pone.0183639.ref064]\] evaluated the economic burden of Irinotecan-related toxicity in patients with metastatic colorectal cancer, revealing that the mean predicted cost per patient was 4,886 €. On the other hand, Arondekar et al. \[[@pone.0183639.ref065]\] investigated the costs of AEs in 2,621 patients with metastatic melanoma by employing multivariate generalized linear models (GLMs) with a log-link function and gamma distribution. They reported a 30-day incremental cost of over 9,000 \$ for metabolic AEs, 8,450 \$ for hematologic, 6,476 \$ for cardiovascular and 6,338 \$ for gastrointestinal AEs \[[@pone.0183639.ref065]\].

Similarly, Bilir et al. \[[@pone.0183639.ref066]\] studied the economic burden of toxicities associated with treating metastatic melanoma in the United States. They registered that the highest mean in patient costs for an AE were associated with acute myocardial infarction, sepsis, and coma, ranging from 31,682 \$ to 47,069 \$. In addition, the mean cost for hospitalization due to other AEs ranged from 19,122 \$ to 26,861 \$ \[[@pone.0183639.ref066]\].

The quantification of the economic impact related to the toxicity of target agents will represent a major step forward in the phases of drug approval and cost establishement, representing a fundamental parameter that must be considered during these processes.

In the last years, several techniques of drug reimboursement have been introduced in the pharmacoeconomic scenario and are currently employed in the oncological field. These modalities include: (1) payment by results, which consists in the total refund by the manyfacturer for non-responding patients; (2) risk sharing, which provides for a partial refund for non-responding patients after a clinical/radiological evalutation; (3) cost sharing, which sets an initial discount for all treated patients. These techniques have become even more fundamental after the introduction of immunotherapy in the therapeutic armamentarium of cancer patients. In fact, these agents are characterized by both relevant cost and high efficacy, supporting the research for new tools aimed to optimize the use of economic resources in the health system. In this respect, Russi et al. \[[@pone.0183639.ref067]\] proposed a new cost-containmet strategy for the use of immunotherapic agent ipilimumab for patients with melanoma in Italy. This model included, by one side, drug-day and centralization of compounding (accounting for a reduction of -11.1% of drug cost) and, by the other side, payback systems designed by AIFA (resulting in additional -6.2%) \[[@pone.0183639.ref067]\].

Our study present several limitations. First of all it is a systematic review realized starting from clinical trials and not from individual patients' data. Thus, data on drug toxicity might be influenced by confounding factors such as the presence of different tumors, patients' comorbidities or simultaneous treatments. Furthermore, patients eligible for clinical trials mostly show fair organ functions, leading to a potential underestimation of drug toxicity compared to clinical practice. Finally, we are awared that the various toxicities considered in our analysis may have a different impact on patient QoL and a wide range of clinical consequences, although we considered only SAEs that lead to patient hospitalization and/or medical interventions and the D rate.

In face of these limitations, at a macroscopic level, our analysis highlights that there is a not straightforward relationship between the toxicity of target agents and their relative costs for 1-month or the whole treatment duration. However, we can notice that the number of target agents with high costs results more relevant in the clusters associated with the worst drug-tolerability (high SAE and D rates), although they belong also to the cluster characterized by better safety (low SAE and D rates).

Interestingly, data on kurtosis and skewness underline that a high percentage of cancer patients treated with molecularly target agents do experience at least one all grade adverse event. The toxicity of these drugs, altough lower than that associated with chemotherapy, suggest that the costs of management of adverse events must be considered during the phases of approval and price negotiation.

To sum up, the relationship between the cost and the efficacy and toxicity of new generation drugs does not follows a regular path. However, the constructed database and the findings here obtained can be efficiently used for the development of a unified theory on the cost management of treating cancer patients and on the study of the impact of these agents on their QoL.
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